RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

NCT06797531 · clinicaltrials.gov ↗

RECRUITING

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

HR+/HER2- Early Breast Cancer

Interventions

DRUG: ribociclib

Sponsor

Novartis Pharmaceuticals